What weight do you need to get Mounjaro on a private prescription?

Step 1: Check your BMI against the licensed thresholds

The licensed eligibility window is the first practical filter. The NHS medicines page for tirzepatide sets out that treatment is indicated for adults with a BMI of 30 or above, or from 27 upwards when a weight-related condition is present. Common qualifying conditions include type 2 diabetes, prediabetes, high blood pressure, raised cholesterol, obstructive sleep apnoea and cardiovascular disease.

BMI alone, though, tells you less than you might expect. It is calculated from height and weight, so two people can share a BMI of 32 and face very different health risks. That is part of why the licence does not simply say "weigh X kg", weight relative to height is the measure, and what sits alongside it matters as much as the number itself. You can run your numbers through the NHS BMI calculator before your consultation if you want a clear figure to hand.

If your BMI sits below 30 but above 27, the weight-related condition requirement is not a technicality to work around. It exists because the clinical evidence for benefit was established in people carrying meaningful health risk alongside excess weight. A prescriber will ask about those conditions specifically, and you should be prepared to discuss your medical history honestly.

Step 2: Understand where ethnic-background thresholds change the picture

Standard BMI cut-offs were developed in predominantly white European populations and do not translate equally across all ethnic groups. NICE's appraisal of tirzepatide, TA1026, recommends that for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, the BMI thresholds should be set 2.5 kg/m² lower. In practice, that means a BMI of 27.5 or above (rather than 30) is the threshold for standard eligibility, and 24.5 or above (rather than 27) with a qualifying condition.

This is not a loophole or a softer standard. It reflects established evidence that cardiometabolic risk rises at lower BMI values in certain populations. If you fall into one of these groups and your BMI sits between those adjusted and standard thresholds, it is worth raising this explicitly when you speak to a prescriber. The clinical framework supports it.

For a fuller breakdown of how weight and BMI interact with the eligibility criteria, our page on what weight you have to be to get Mounjaro covers the specific thresholds in more detail.

Step 3: Know how private eligibility differs from NHS access

The NHS route to tirzepatide is narrower and significantly more structured. NICE TA1026 specifies a BMI of 35 or above with at least one qualifying comorbidity, and the NHS is rolling out access in phases, currently prioritising people with the highest BMI and the greatest number of conditions. That rollout is real but slow; for many people who meet the licensed private criteria, NHS access is either not yet available to them or involves a long wait through a specialist service.

Private prescribing through a GPhC-registered pharmacy works within the manufacturer's licensed indications rather than the stricter NHS commissioning criteria. That is a legitimate distinction, not a workaround. The clinical standards still apply: a prescriber reviews every consultation, identity is verified, and the medicine travels through the authorised UK supply chain.

If you want to understand how the private process works end to end, how to get Mounjaro for weight loss walks through each step from consultation to delivery. The first pen arrives in plain packaging via tracked DPD, the box gives nothing away from the outside.

Step 4: What a prescriber actually looks at beyond the BMI threshold

Meeting the BMI figure gets you to the consultation. It does not complete it. Before writing a prescription, a GPhC-registered prescriber reviews your current medications for interactions, asks about your history with pancreatitis or gallbladder problems, checks for contraindications such as personal or family history of certain thyroid conditions, and considers whether any other aspect of your health changes the risk-benefit balance.

Mounjaro is a dual GIP and GLP-1 receptor agonist, the only one of its kind licensed for weight management in the UK. The clinical evidence is substantial (SURMOUNT-1 showed an average body-weight reduction of around 20 to 21% at the 15mg dose over 72 weeks in people without diabetes) but those results were achieved in people who were clinically assessed before starting, not self-selected. If you want to understand more about how Mounjaro affects weight and what the clinical data shows, that detail is worth reviewing before your consultation.

On cost, Mounjaro is a private prescription and priced accordingly. The Mounjaro pricing page gives market context without surprises. At nume, one transparent price covers the consultation, the prescription, the medicine and next-working-day delivery, no separate fees at each stage.

If you are ready to find out whether you're clinically suitable, speak to our prescribers through a free consultation. A real clinician reads your answers the same day.